---
stable_id: R-HSA-9712078
display_name: ALK mutants bind PI3KR1
species: Homo sapiens
summary: Various ALK fusions and point mutants have been shown to form stable, active
  complexes with the PI3K and to activate downstream signaling through AKT/PKB (Bai
  et al, 2000; Slupianek et al, 2001; Slupianek and Tomasz, 2004; Marzec et al, 2007;
  Chen et al, 2008; Chand et al, 2013; George et al, 2008; Janoieux-Lerousey et al,
  2008; Wong et al, 2011; Cerchietti et al, 2011; Wiesner et al, 2014; Koivunen et
  al, 2008; Ren et al, 2012; Cazes et al, 2013; Okubo et al, 2103; reviewed in Della
  Corte et al, 2018; Hallberg and Palmer, 2013; Ducray et al, 2019). Attempts to define
  a binding site for the p85 regulatory subunit of PI3K on NPM-ALK identified fragment
  with a putative p85 phospho-tyrosine binding site that was capable of blocking the
  interaction of PIK3R1 when co-expressed. In spite of this, mutation of the putative
  tyrosine residue did not block PIK3R1 binding, suggesting that the interaction may
  be mediated by an adaptor protein. SHC, CRKL and GAB2 each formed complexes with
  both PIK3R1 and NPM-ALK as assessed by co-immunoprecipitation, making them candidates
  (Bai et al, 2000).<br>Signaling through the PI3K/AKT pathway activates the anti-apoptotic
  pathway contributing to oncogenesis (Bai et al, 2000; Slupianek et al, 2001; reviewed
  in Rososki, 2013; Ducray et al, 2019).
---

# ALK mutants bind PI3KR1
**Reactome ID:** [R-HSA-9712078](https://reactome.org/content/detail/R-HSA-9712078)
**Species:** Homo sapiens

## Summary

Various ALK fusions and point mutants have been shown to form stable, active complexes with the PI3K and to activate downstream signaling through AKT/PKB (Bai et al, 2000; Slupianek et al, 2001; Slupianek and Tomasz, 2004; Marzec et al, 2007; Chen et al, 2008; Chand et al, 2013; George et al, 2008; Janoieux-Lerousey et al, 2008; Wong et al, 2011; Cerchietti et al, 2011; Wiesner et al, 2014; Koivunen et al, 2008; Ren et al, 2012; Cazes et al, 2013; Okubo et al, 2103; reviewed in Della Corte et al, 2018; Hallberg and Palmer, 2013; Ducray et al, 2019). Attempts to define a binding site for the p85 regulatory subunit of PI3K on NPM-ALK identified fragment with a putative p85 phospho-tyrosine binding site that was capable of blocking the interaction of PIK3R1 when co-expressed. In spite of this, mutation of the putative tyrosine residue did not block PIK3R1 binding, suggesting that the interaction may be mediated by an adaptor protein. SHC, CRKL and GAB2 each formed complexes with both PIK3R1 and NPM-ALK as assessed by co-immunoprecipitation, making them candidates (Bai et al, 2000).<br>Signaling through the PI3K/AKT pathway activates the anti-apoptotic pathway contributing to oncogenesis (Bai et al, 2000; Slupianek et al, 2001; reviewed in Rososki, 2013; Ducray et al, 2019).
